Precise minimally invasive treatment of VT using non-invasive mapping

使用无创标测精确微创治疗 VT

• 批准号: 8314436
• 负责人: Dwight Meglan
• 金额: $ 34.67万
• 依托单位: HEARTLANDER SURGICAL, INC.
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-05 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8314436
• 关键词: Ablation; Address; Affect; Animal Model; Area; Arrhythmia; Catheters; Cessation of life; Coronary; Coronary Arteriosclerosis; Devices; Evaluation; Funding; General Population; Heart; Hour; Hypertension; Implantable Defibrillators; Injury; Life; Location; Maps; Myocardium; Nature; Needles; Pain; Patients; Phase; Population; Procedures; Public Health; Publishing; Radiofrequency Interstitial Ablation; Reporting; Research; Shock; Side; Site; Small Business Innovation Research Grant; Structure; Surface; Syncope; System; Techniques; Technology; Time; Tissues; United States; United States National Institutes of Health; Ventricular Tachycardia; Walkers; Work; base; cost effective; experience; flexibility; minimally invasive; novel; prevent; success; voltage

DESCRIPTION (provided by applicant): Ventricular Tachycardia (VT) is a major public health problem occurring in 15% of patients with coronary artery disease, 8% of patients with hypertension, and 2% of the general population. Current therapy is placement of an implantable cardioverter- defibrillator (ICD). While ICDs are effective in terminating VT, they do not prevent VT from occurring. Permanent cessation of VT can result from identification and selective ablation of the origination site(s) of the arrhythmia. This technique unfortunately can only be applied to small number of VT patients because it requires their having slow, hemodynamically stable VT to be safe. Using three proven technologies, we will create a novel means of minimally invasively identifying and ablating VT initiation sites that is applicable to a much largr number of VT patients. By combining a non-invasive mapping technology with a precise epicardial navigation approach and a flexible needle- based radio frequency ablation technique, we will produce a uniquely capable system. In Phase I of this work, we will demonstrate that these technologies can be unified while in Phase II we will verify its efficacy in an animal model. PUBLIC HEALTH RELEVANCE: Ventricular Tachycardia (VT) is a major public health issue in the United States resulting in 300,000 deaths each year. An implantable cardioverter-defibrillator is considered the most appropriate means of treatment at present. Unfortunately, this does not prevent VT but rather stops the arrhythmia with a painful shock. To permanently treat VT, its origination must be prevented, but this can presently be done on only a small percentage of the VT-affected population. The therapy that will be developed through this proposal will significantly expand the number of VT patients who can have this permanent cessation technique and will do so using a safe, cost-effective approach that builds upon several well-understood technologies. !

描述（由申请人提供）：室性心动过速（VT）是一种主要的公共卫生问题，发生在15%的冠状动脉疾病患者、8%的高血压患者和2%的普通人群中。目前的治疗方法是植入心律转复除颤器（ICD）。虽然ICD在终止VT方面是有效的，但它们不能防止VT的发生。室性心动过速的永久停止可以通过识别和选择性消融心律失常的起源部位来实现。不幸的是，这种技术只能应用于少数VT患者，因为它需要他们具有缓慢的、血流动力学稳定的VT才是安全的。使用三种成熟的技术，我们将创造一种新的方法，微创识别和消融室性心动过速起始部位，适用于更大数量的室性心动过速患者。通过将非侵入性标测技术与精确的心外膜导航方法和灵活的基于针的射频消融技术相结合，我们将生产出一种独特的系统。在这项工作的第一阶段，我们将证明这些技术可以统一，而在第二阶段，我们将在动物模型中验证其有效性。 公共卫生相关性：室性心动过速（VT）是美国的一个主要公共卫生问题，每年导致30万人死亡。植入式心律转复除颤器被认为是目前最合适的治疗手段。不幸的是，这并不能防止室性心动过速，而是通过痛苦的电击停止心律失常。要永久治疗室性心动过速，必须预防其起源，但目前只能在一小部分受室性心动过速影响的人群中进行。通过该提案开发的治疗将显著增加可以使用这种永久停止技术的VT患者的数量，并将使用基于几种众所周知的技术的安全，具有成本效益的方法来实现。!